Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Stage IIB Lung Cancer AJCC v8: early-phase trial registry

7 of 13 indexed Stage IIB Lung Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,315 of 28,707 conditions by registered trial count.

13 US clinical trials · 7 currently recruiting · #1,315 of 28,707 conditions by registered trial count

Stage IIB Lung Cancer AJCC v8: 13 US clinical trials tracked, 7 recruiting.

Stage IIB Lung Cancer AJCC v8 is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 6 of these trials.

Enrollment posture brief

Registry condition stage-iib-lung-cancer-ajcc-v8

OPEN 7 | RECR 54% | LATE 1 | EARLY 7 | RANK #1315 | SPON 6

Nearest open-share peer: Advanced Renal Cell Carcinoma (54% recruiting · 13 trials)

ACL Injury61.5%Stage IIB Lung Cancer AJ (th…54%Acute Biphenotypic Leukemia46.2%Accidental Falls30.8%Actinic Keratoses23.1%
Open-enrollment share among volume-matched conditions near Stage IIB Lung Cancer AJCC v8

Stage IIB Lung Cancer AJCC v8 lists 7 open slots (54% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage IIB Lung Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage IIB Lung Cancer AJCC v8 is recruiting above its size-band peers.

    7 of 13 indexed trials (53.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage IIB Lung Cancer AJCC v8 research.

    M.D. Anderson Cancer Center accounts for 6 of 13 trials (46.2%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Stage IIB Lung Cancer AJCC v8 trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 13 trials that report a genuine target (sentinel values excluded). 8 of those (61.5%) plan for fewer than 100 participants.

  4. Stage IIB Lung Cancer AJCC v8 research is mostly interventional.

    13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 24Phase 31

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3 474 participants

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NRG Oncology

NCT05624996

RECRUITING NA 400 participants

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

M.D. Anderson Cancer Center

NCT03948100

RECRUITING Phase 2 220 participants

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Roswell Park Cancer Institute

NCT04067830

RECRUITING NA 150 participants

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

Roswell Park Cancer Institute

NCT05292521

RECRUITING Phase 2 50 participants

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

M.D. Anderson Cancer Center

NCT04789681

RECRUITING NA 34 participants

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

Rutgers, The State University of New Jersey

NCT04751747

RECRUITING Phase 1 28 participants

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

NCT05136846

ACTIVE NOT RECRUITING NA 8,300 participants

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

National Cancer Institute (NCI)

NCT02194738

ACTIVE NOT RECRUITING NA 70 participants

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

M.D. Anderson Cancer Center

NCT03731585

ACTIVE NOT RECRUITING Phase 2 45 participants

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

M.D. Anderson Cancer Center

NCT03634241

ACTIVE NOT RECRUITING Phase 1 34 participants

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

NCT04505267

ACTIVE NOT RECRUITING Phase 1 21 participants

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

M.D. Anderson Cancer Center

NCT04013542

ACTIVE NOT RECRUITING Phase 2 5 participants

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

University of Southern California

NCT05340309

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Stage IIB Lung Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
4 trials
Quality-of-Life Assessment Other
4 trials
Computed Tomography Procedure
4 trials
Radiation Therapy Radiation
3 trials
Carboplatin Drug
3 trials
Educational Intervention Other
2 trials
Best Practice Other
2 trials
Durvalumab Biological
2 trials

US sites by state

Facility locations filed on Stage IIB Lung Cancer AJCC v8 trials. A trial with sites in several states counts in each.

Texas 6 trials
New York 3 trials
California 3 trials
Arizona 2 trials
Alabama 2 trials
Ohio 1 trials
New Jersey 1 trials
Arkansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage IIB Lung Cancer AJCC v8 page

13 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIB Lung Cancer AJCC v8 condition card totals 13 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.